Study Comparing Venlafaxine vs. Paroxetine in Panic Disorder
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
The purpose of this pilot study is to evaluate the improvement in social function following therapy with venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine. An additional purpose of this pilot study is to obtain the tolerability of using venlafaxine extended release (XR) in the treatment of panic disorder (PD) in comparison to paroxetine.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years to 65 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Meet DSM IV criteria for Panic Disorder (with or without agoraphobia) for at least 3 months before study day 1.
Have a minimum of 8 full-symptom panic attacks during the 4 weeks before the screening visit.
Provide a written informed consent
Treatment with Venlafaxine within 6 months of study day 1, as well Paroxetine
Known hypersensitivity to Venlafaxine or related compounds as well to Paroxetine.
Psychopharmacologic drugs within 14 days of study day 1